Orly 120 mg 30 capsules

Trade name:

Orly

Orly

Properties

Lipase inhibitor. When taken orally, orlistat inhibits gastric and pancreatic lipases. As a result, the breakdown of dietary fats is disrupted and their absorption from the gastrointestinal tract is reduced. With systematic use, this effect leads to a decrease in body weight in obese patients. Orlistat is practically not absorbed from the gastrointestinal tract and therefore has practically no resorptive effect.

Indications

Obesity (combined with a moderate calorie diet).

Dosage and administration

The optimal dosage regimen is determined by the doctor. Compliance of the dosage form of a particular drug with indications for use and dosing regimen should be strictly observed.

inside. The recommended dose is 120 mg 3 times / day with meals.

The duration of the course of treatment is no more than 6 months.

Contraindications

Hypersensitivity to orlistat; chronic malabsorption syndrome, cholestasis; simultaneous use with warfarin or other oral anticoagulants of indirect action, concomitant therapy with cyclosporine, simultaneous use with sitagliptin; pregnancy, lactation (breastfeeding); children and adolescents up to 18 years of age.

Precautionary measures:

Diet and exercise are an important component of a weight loss program. It is recommended that diet and exercise be initiated prior to initiating orlistat therapy. During the period of use of orlistat, the patient should receive a moderately hypocaloric diet with a balanced content of nutrients, in which approximately 30% is fat. It is recommended that the food be rich in fruits and vegetables. The diet and exercise program should continue after orlistat is discontinued.

Side effects

From the digestive system: very often — oily discharge from the rectum, passing gases with some discharge, imperative urge to defecate, steatorrhea, flatulence; often — abdominal pain, fecal incontinence, loose stools, increased bowel movements; frequency is unknown — minor bleeding from the rectum, diverticulitis, pancreatitis.

From the side of the liver and biliary tract: the frequency is unknown — increased activity of «liver» transaminases, alkaline phosphatase, hepatitis, cholelithiasis.

From the urinary system: the frequency is unknown — hyperoxalaturia, oxalate nephropathy, which can sometimes lead to the development of renal failure.